Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2007, Thuja Capital is an early-stage venture capital firm based in Utrecht, Netherlands. The firm specializes in investing in innovative life science companies, particularly in the biotech and medtech sectors. With a strong commitment to addressing significant unmet medical needs, Thuja Capital aims to translate breakthrough scientific advancements from the laboratory into clinical applications. Over the years, the firm has built a reputation for its strategic approach to investment, focusing on both financial backing and operational support to help portfolio companies navigate the challenges of early-stage development. As of now, Thuja Capital manages a portfolio of 24 companies, showcasing its active engagement in the European life sciences ecosystem. The firm is known for its rigorous selection process and its dedication to fostering innovation in healthcare, making it a sought-after partner for startups in the biotech and healthcare sectors.
Thuja Capital primarily invests in biotech and medtech companies that are working to address significant unmet medical needs. The firm seeks to identify innovative solutions that have the potential to transform healthcare and improve patient outcomes. Their investment strategy is centered around translating scientific advancements into practical clinical applications, which involves not only providing capital but also offering strategic, technical, and operational support to portfolio companies. This support is crucial for helping startups overcome initial challenges and achieve key milestones in their development. Thuja Capital's geographic focus is primarily on Europe, where it aims to partner with visionary founders and teams that are committed to making a meaningful impact in the life sciences sector. The firm typically engages with companies at the pre-seed and seed stages, allowing them to play a pivotal role in the early development of groundbreaking healthcare solutions.
Thuja Capital boasts a diverse portfolio of 24 innovative companies in the biotech and healthcare sectors. Notable investments include Alesta Therapeutics, which focuses on developing novel therapies for cancer, and ArgenX, known for its groundbreaking work in immunology. Other significant portfolio companies include CardiacBooster, which is dedicated to improving heart health, and Artica Therapeutics, which is working on advanced treatments for autoimmune diseases. The firm’s portfolio reflects its commitment to supporting companies that are at the forefront of scientific innovation and are poised to make a substantial impact in the healthcare landscape. By providing both financial resources and strategic guidance, Thuja Capital plays an essential role in helping these companies navigate the complexities of bringing their products to market.
Harrold van Barlingen - Founder and Managing Partner. Harrold has extensive experience in the life sciences sector and leads Thuja Capital's investment strategy, focusing on innovative biotech and medtech companies.
To pitch Thuja Capital, founders should email their proposals to info@thujacapital.com. The firm is open to cold applications and encourages startups in the biotech and healthcare sectors to present their innovative ideas. A well-structured pitch should include details about the company's vision, the problem it addresses, and how it plans to translate scientific advancements into clinical applications.
Recently, Thuja Capital published their 2024 Impact & ESG Annual Report, highlighting their commitment to transparency and accountability in investment practices. This report underscores their active engagement in evaluating and reporting on their impact within the life sciences sector.
Thuja Capital focuses on early-stage investments, specifically at the pre-seed and seed stages. This allows them to support innovative companies from their inception, helping them to develop their ideas into viable products.
The firm specializes in the biotech and medtech sectors, investing in companies that address significant unmet medical needs. Their focus is on innovative life science solutions that can translate scientific advancements into clinical applications.
While specific check sizes are not disclosed, Thuja Capital typically invests in early-stage companies, which often involves smaller initial investments that can grow as the company develops and meets key milestones.
Thuja Capital primarily invests in Europe, focusing on innovative life science companies within this region. Their geographic focus allows them to leverage local expertise and networks in the biotech and healthcare sectors.
Founders interested in pitching to Thuja Capital can reach out via email at info@thujacapital.com. The firm welcomes inquiries from innovative life science companies looking for early-stage funding and support.
In addition to financial investment, Thuja Capital offers strategic, technical, and operational support to its portfolio companies. This assistance is designed to help startups overcome initial challenges and achieve critical milestones in their development.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.